Interphil Laboratories, Inc. vs. OEP Philippines, Inc.

Under the doctrine of res ipsa loquitur, a manufacturer exercising exclusive control over the packaging process is presumed negligent when a packaging defect occurs that would not ordinarily happen absent negligence, and the injured party is relieved of the burden of producing specific proof of negligence. A party's unilateral destruction of defective products posing health risks to consumers does not constitute bad faith or breach of contract where the agreement vests it with discretion over disposition of substandard batches and immediate action is necessary to prevent public injury.

Interphil Laboratories, Inc. is a corporation engaged in the business of processing and packaging pharmaceutical and other products, while OEP Philippines, Inc. (formerly known as Elan Pharmaceutical Corporation) trades, among others, 60-, 90-, 120-, and 180-milligram Diltelan capsules. In 1998, the parties entered into a Manufacturing Agreement under which Interphil undertook to process and package 90- and 120-mg Diltelan capsules for OEP, following formulae, standards, and instructions supplied by OEP. The Agreement allocated liability for defective products according to the source of the defect: if the cause lay in the manufacturing process or packaging, Interphil would assume liability; if the cause lay in the formulae, process, methods, instructions, or raw materials provided by OEP, the latter would assume liability. To comply with Department of Health Administrative Order No. 56, Series of 1989, the parties jointly informed the Bureau of Food and Drugs that they agreed to be jointly responsible for product quality, without prejudice to the allocation of liability after determination of the cause of any defect.

Interphil Laboratories, Inc. and OEP Philippines, Inc. entered into a Manufacturing Agreement sometime in 1998, under which Interphil undertook to process and package 90- and 120-mg Diltelan capsules for OEP, following formulae, standards, and instructions supplied by OEP. The Agreement required Interphil to prepare and pack the products strictly in accordance with the formulae, processes, standards, techniques, and designs furnished by OEP, and to conduct quality control and other tests as OEP specified. Under Section VI of the Agreement, if a batch failed to meet processing or packaging standards, Interphil was to either correct the deficiency or destroy the batch on OEP's instructions, with expenses borne by OEP unless the failure was attributable to Interphil's non-observance of OEP's written instructions or the negligence of Interphil's personnel. The parties also issued a joint letter to the Bureau of Food and Drugs stating that if the cause of a defect was the manufacturing process or packaging, Interphil would assume liability, and if the cause was the formulae, process, methods, instructions, or raw materials provided by OEP, the latter would assume liability.

From January 1999 to May 2000, Interphil accepted delivery of several 90- and 120-mg Diltelan capsules, as well as printed foils and boxes for these capsules, for processing and packaging pursuant to the Agreement. Interphil charged OEP a packaging fee and a "packaging materials inspection fee" in consideration of Interphil's commitment to inspect the materials delivered to its plant. Thereafter, Interphil sorted, wrapped, and boxed the capsules, and delivered the finished products to OEP, which in turn delivered them to its client, Orient Eropharma Co., Ltd./Elan Pharma Ltd. of Taiwan (Elan Taiwan).

The conflict arose on August 8, 2000, when OEP received a facsimile from Elan Taiwan reporting that several hospitals in Taiwan had complained of a packaging defect in 90-mg Diltelan capsules. Specifically, several 90-mg capsules had been inadvertently wrapped in foils meant and labeled for 120-mg capsules and then placed in boxes meant and labeled for 90-mg capsules. OEP immediately informed Interphil of the defect. Investigations by both parties revealed that the defectively packaged capsules belonged to a single batch, Lot No. 001369, which Interphil had processed and packaged in April 2000.

Because of the danger and health risks posed by the defective packaging, OEP recalled and destroyed all capsules belonging to Lot No. 001369, incurring numerous costs and expenses totaling ₱5,183,525.05. OEP demanded reimbursement from Interphil, but Interphil refused to pay. OEP then filed a complaint with the RTC of Makati City. The RTC found Interphil negligent under the doctrine of res ipsa loquitur and rejected Interphil's defense that OEP had breached the Agreement by unilaterally destroying the products without following the agreed procedure. The CA affirmed, finding that the proximate cause of the damage was Interphil's erroneous packaging, which was within its exclusive control, and that OEP's unilateral recall and destruction was a prudent measure to prevent further injury to the public.

• Procedural Defect Excused: Petitioner argued that the Petition should not be dismissed on the basis of a technicality, considering that the failure to serve the CA with a copy of the Petition had been rectified through furnishing a copy to the CA on March 25, 2013.
• Inapplicability of Res Ipsa Loquitur: Petitioner maintained that the requisites of res ipsa loquitur did not apply because, while it had exclusive control over the plant where packaging was effected, it had no exclusive control over the packaging materials supplied by OEP, and the cause of the injury was the mis-splicing of the foil — a defect in the packaging materials supplied by OEP. Petitioner stressed that it could not have discovered the mis-splicing even after investigation, and that inspection of the packaging materials was limited to checking whether they were deformed or in sufficient quantity.
• OEP's Contributory Fault: Petitioner argued that OEP failed to exercise due care in providing distinguishable packaging materials, and that the packaging materials were defective to begin with due to the similarity in design of the 90- and 120-mg foils, the mis-splicing in the foil, and the alleged failure to properly flag the splices.
• Failure of Proof of Negligence: Petitioner asserted that OEP failed to overcome its burden of proof to establish negligence, offering only the David Beff Report which actually emphasized that the mix-up could have been initiated at the printing stage of the packaging materials.
• Proximate Cause: Petitioner argued that even if its failure to detect the mis-splicing constituted negligence, such negligent act was not the proximate cause of the injury, as OEP's prior acts — the similarity in design of the packaging materials, the mis-splicing, and the failure to flag splices — were part of the natural and continuous sequence of events leading to the damage.
• Breach by OEP: Petitioner accused OEP of unilaterally destroying the products instead of possibly reworking or repackaging them, contrary to the provisions of the Agreement, without informing Interphil or giving it a chance to rectify the situation. Petitioner contended this also violated DOH Administrative Order No. 43, Series of 1999, relating to the proper destruction of pharmaceutical products.

• Fatal Procedural Defect: Respondent contended that the Petition was fatally defective for failure to serve the CA with a copy of the Petition prior to filing, prompting the CA to issue an Entry of Judgment on March 8, 2013. Respondent submitted that the Petition should be dismissed outright for failing to comply with the mandatory requirements of Rule 45, noting that Interphil served a copy to the CA almost five months after it should have done so.
• Questions of Fact Beyond Jurisdiction: Respondent argued that the Petition improperly raised pure questions of fact, which are beyond the Supreme Court's jurisdiction, and that the concurrent factual findings of the RTC and CA are binding and conclusive.
• Res Ipsa Loquitur Established: Respondent asserted that the error was committed at the time of packaging and within Interphil's exclusive control, and that nothing in the records showed that OEP contributed to the incident. The fact of mis-splicing was never established with clear and preponderant evidence, and the processing and packaging were entirely in Interphil's hands.
• No Breach in Destruction of Products: Respondent pointed to the Agreement, which does not bar OEP from correcting or destroying the subject capsules and recognizes OEP's absolute discretion in deciding what to do with defective products. Respondent satisfactorily explained the danger and health risks posed by the defectively packaged capsules, justifying the immediate recall and destruction.

• Procedural Compliance: Whether the Petition must be dismissed outright due to Interphil's failure to timely serve the CA with a copy of the Petition, as required under Rule 45 of the Rules of Court.
• Negligence Under Res Ipsa Loquitur: Whether Interphil was negligent based on the doctrine of res ipsa loquitur.
• Breach by OEP: Whether OEP can be held liable for breach of the Agreement due to its unilateral destruction of the products.

• Procedural Compliance: No. The Court invoked liberality and allowed the Petition, the procedural lapse having been subsequently rectified by Interphil's furnishing of a copy to the CA.
• Negligence Under Res Ipsa Loquitur: Yes. All three elements of res ipsa loquitur were established: the accident would not have happened absent negligence, the packaging process was under Interphil's exclusive control, and OEP contributed no voluntary act causing the injury.
• Breach by OEP: No. OEP's unilateral destruction of the defective products was a prudent measure to prevent public health risks, not a breach of the Agreement, and no bad faith was shown.

• Procedural Compliance: The Court noted that Rule 45 requires proof of service of the petition on the lower court and adverse party, and that failure to comply is sufficient ground for dismissal. However, citing Pagdonsalan vs. NLRC and Sunrise Manning Agency, Inc. vs. NLRC, the Court held that the failure to furnish a copy to the CA was a mere formal lapse and excusable neglect, not a jurisdictional defect. Interphil admitted the error and belatedly rectified it by furnishing a copy to the CA. The Court invoked the policy of refraining from dismissing cases on mere technicalities and allowed the Petition to proceed.

• Negligence Under Res Ipsa Loquitur: The Court found that the factual findings of both the RTC and CA were consistent in holding Interphil liable, and absent any showing of arbitrariness, the Court was bound by those findings, as it is not a trier of facts in a petition for review on certiorari. The elements of res ipsa loquitur, as enumerated in Cortel vs. Gepaya-Lim, were satisfied: (1) the packaging defect was of such character that it would not have happened except for Interphil's negligence — 90-mg capsules were wrapped in 120-mg labeled foils, an error that should not occur if proper care is exercised; (2) the packaging process was under Interphil's exclusive management and control — Interphil itself admitted that its personnel inspected the materials upon delivery and that it charged OEP inspection fees, undermining its claim that the materials were defective when received; and (3) the accident was not due to any voluntary action or contribution by OEP — even if OEP supplied similar-looking foils, that was not the proximate cause, as it was clearly the erroneous packaging that caused the recall and destruction. The joint letter to the BFD itself stated that if the cause of the defect was the manufacturing process or packaging, Interphil would assume liability. Interphil failed to adduce substantial proof of its claim that the foil was already mis-spliced when received from OEP, offering only bare assertions.

• Breach by OEP: The Court found that OEP sufficiently rebutted the presumption of fault or negligence. The provisions cited by Interphil did not bar OEP from exercising discretion regarding destruction of defectively packaged capsules. OEP demonstrated that immediate destruction was necessary because of the danger and health risks posed to the public by the wrong packaging — 90-mg capsules in 120-mg labeled foils could lead to incorrect dosing. The Court agreed with the CA that OEP's action was a prudent move to prevent contamination and protect consumer safety. Spending time corresponding with Interphil or allowing it to rectify the situation would have aggravated an already precarious situation. The statutory presumption of good faith stood unrebutted, as Interphil failed to adduce evidence of bad faith on OEP's part. The Court also found Interphil liable for actual or compensatory damages (₱5,183,525.05 for costs and expenses and ₱306,648.81 for unrealized profits), exemplary damages (₱100,000.00) under Article 2232 of the Civil Code due to Interphil's gross negligence which endangered consumer health, and attorney's fees (₱50,000.00) as OEP was compelled to litigate.

• Res Ipsa Loquitur — A doctrine of evidentiary proof for negligence permitting an inference or presumption of negligence where: (1) the accident is of such character as to warrant an inference that it would not have happened except for the defendant's negligence; (2) the accident was caused by an agency or instrumentality within the exclusive management or control of the defendant; and (3) the accident was not due to any voluntary action or contribution on the part of the person injured. The doctrine serves as a substitute for specific proof of negligence, relieving the plaintiff of that burden and shifting it to the defendant to prove absence of negligence. In this case, all three elements were satisfied because Interphil had exclusive control over the packaging process, the mispackaging would not have occurred absent negligence, and OEP contributed no voluntary act causing the injury.

• Culpa Contractual — Under Article 1170 of the Civil Code, those who in the performance of their obligations are guilty of fraud, negligence, or delay, or who in any manner contravene the tenor thereof, are liable for damages. Mere proof of the existence of the contract and failure of compliance justify, prima facie, a corresponding right of relief. The Court applied this doctrine in evaluating Interphil's claim that OEP breached the Agreement by unilaterally destroying the products, finding that OEP's actions did not contravene the Agreement's tenor.

• Actual or Compensatory Damages — Under Articles 2199 and 2200 of the Civil Code, actual or compensatory damages are awarded in satisfaction of or recompense for loss or injury sustained. There are two kinds: the loss of what a person already possesses, and the failure to receive as a benefit that which would have pertained to him (unrealized profits or ganancias frustradas / lucrum cessans). Absolute certainty as to the amount is not required when the existence of a loss is established; the injured party must produce the best evidence available and if that evidence warrants the inference of lost profits with reasonable certainty, recovery is proper. The Court awarded both types to OEP.

• Exemplary Damages — Under Article 2232 of the Civil Code, exemplary damages may be awarded when the defendant in a contract or quasi-contract acted in a wanton, fraudulent, reckless, oppressive, or malevolent manner. Exemplary damages serve as a deterrent to future wrongdoings. The Court awarded exemplary damages because Interphil's gross negligence not only prejudiced the contractual relationship but also endangered the health of end consumers, as evidenced by hospital reports of the defect.

• Statutory Presumption of Good Faith — A party is presumed to act in good faith unless proven otherwise. The Court applied this presumption in favor of OEP, finding that Interphil failed to adduce evidence sufficient to rebut it regarding OEP's unilateral destruction of the defective products.

• "While negligence is not ordinarily inferred or presumed, and while the mere happening of an accident or injury will not generally give rise to an inference or presumption that it was due to negligence on defendant's part, under the doctrine of res ipsa loquitur, which means, literally, the thing or transaction speaks for itself, or in one jurisdiction, that the thing or instrumentality speaks for itself, the facts or circumstances accompanying an injury may be such as to raise a presumption, or at least permit an inference of negligence on the part of the defendant, or some other person who is charged with negligence." — This passage, quoted from Cortel vs. Gepaya-Lim, provides the canonical formulation of the res ipsa loquitur doctrine as applied in Philippine jurisprudence.

• "The elements of res ipsa loquitur are: (1) the accident is of such character as to warrant an inference that it would not have happened except for the defendant's negligence; (2) the accident must have been caused by an agency or instrumentality within the exclusive management or control of the person charged with the negligence complained of; and (3) the accident must not have been due to any voluntary action or contribution on the part of the person injured." — This is the three-element test for res ipsa loquitur as adopted by the Court, frequently cited in subsequent negligence jurisprudence.

• "In culpa contractual the mere proof of the existence of the contract and the failure of its compliance justify, prima facie, a corresponding right of relief. The law, recognizing the obligatory force of contracts, will not permit a party to be set free from liability for any kind of misperformance of the contractual undertaking or a contravention of the tenor thereof." — This passage, quoted from RCPI vs. Verchez, articulates the principle of culpa contractual and the obligatory force of contracts, which the Court applied in evaluating whether OEP breached the Agreement.

• "When the existence of a loss is established, absolute certainty as to its amount is not required. The benefit to be derived from a contract which one of the parties has absolutely failed to perform is of necessity to some extent, a matter of speculation, but the injured party is not to be denied for that reason alone." — This passage, quoted from Producers Bank of the Philippines vs. CA, states the standard for proving unrealized profits as actual or compensatory damages, allowing recovery where the evidence warrants a reasonable inference of lost profits.

• Pagdonsalan vs. NLRC, 212 Phil. 426 (1984) — Followed. The Court cited this case for the proposition that failure to furnish a copy of the petition to the lower court is a mere formal lapse and excusable neglect, not a jurisdictional defect warranting dismissal, and that the Court may act on the petition and simply require compliance.
• Sunrise Manning Agency, Inc. vs. NLRC, 485 Phil. 426 (2004) — Followed. The Court relied on this case to reiterate the relaxation of procedural rules for excusable reasons, supporting its decision to allow the Petition despite the procedural lapse.
• Pascual vs. Burgos, 776 Phil. 167 (2016) — Followed. The Court cited this case for the rule that only questions of law may be raised in a petition for review on certiorari, that the CA's factual findings are binding, and that exceptions must be alleged, substantiated, and proved.
• Cortel vs. Gepaya-Lim, 802 Phil. 779 (2016) — Followed. The Court quoted this case extensively for the definition, elements, and evidentiary function of the doctrine of res ipsa loquitur.
• RCPI vs. Verchez, 516 Phil. 725 (2006) — Followed. The Court cited this case for the doctrine of culpa contractual under Article 1170 of the Civil Code.
• Casiño, Jr. vs. CA, 507 Phil. 59 (2005) — Followed. The Court cited this case for the definition and purpose of actual or compensatory damages under Articles 2199 and 2200 of the Civil Code.
• Producers Bank of the Philippines vs. CA, 417 Phil. 646 (2001) — Followed. The Court cited this case for the standard of proof for unrealized profits (ganancias frustradas), holding that absolute certainty as to amount is not required when the existence of a loss is established.
• Terminal Facilities & Services Corp. vs. Philippine Ports Authority, 428 Phil. 99 (2002) — Followed. The Court cited this case for the two kinds of actual or compensatory damages and the standard for awarding unrealized profits.
• Arco Pulp and Paper Co., Inc. vs. Lim, 737 Phil. 133 (2014) — Followed. The Court cited this case for the purpose and nature of exemplary damages as a deterrent to serious wrongdoings.
• Spouses Alcaraz vs. Arante, 700 Phil. 614 (2012) — Cited by petitioner. The Court noted this case for the exception allowing review of factual findings when the CA fails to notice relevant facts that would justify a different conclusion, but found no such failure here.

• Rule 45, Sections 3 and 5, Rules of Court — Require proof of service of the petition on the lower court and adverse party, and provide that failure to comply is sufficient ground for dismissal. The Court invoked liberality in applying these provisions, allowing the Petition despite Interphil's belated service on the CA.
• Article 1170, Civil Code — Provides that those who in the performance of their obligations are guilty of fraud, negligence, or delay, and those who in any manner contravene the tenor thereof, are liable for damages. Applied to evaluate whether OEP breached the Agreement and to establish Interphil's liability for negligent performance.
• Articles 2199 and 2200, Civil Code — Define actual or compensatory damages as those awarded in satisfaction of or recompense for loss or injury sustained. Applied to award OEP ₱5,183,525.05 for costs and expenses incurred and ₱306,648.81 for unrealized profits.
• Article 2232, Civil Code — Authorizes the court to award exemplary damages if the defendant in a contract or quasi-contract acted in a wanton, fraudulent, reckless, oppressive, or malevolent manner. Applied to award ₱100,000.00 in exemplary damages due to Interphil's gross negligence endangering consumer health.
• DOH Administrative Order No. 56, Series of 1989, Section 2.2.2.1 — Requires entities applying for a license to operate as drug manufacturers, traders, or distributors to demonstrate capacity to assure the safety, efficacy, and quality of drug products. The parties' joint letter to the BFD complying with this provision allocated liability for defects between them.
• DOH Administrative Order No. 43, Series of 1999 — Relates to the proper destruction of pharmaceutical products. Interphil alleged OEP violated this regulation by unilaterally destroying the products, but the Court found OEP's actions justified as a prudent health-protective measure.

Peralta (Chairperson), Leonen, Hernando, and Carandang, JJ., concurred. No separate concurring opinions were filed.